A new stem cell therapy in clinical trials is giving hope to patients with serious cornea injuries, according to a recent study published in Nature Communications. This new method shows good results in fixing corneal damage that was once thought untreatable. It could change eye health for people with serious corneal diseases. This includes Black patients who may face challenges in getting eye care.
What is the Treatment?
The cornea is crucial for focusing light onto the retina. When injuries or diseases damage its ability to regenerate new cells, vision can be severely compromised. The new treatment is called cultivated autologous limbal epithelial cells (CALEC). It uses adult stem cells from a patient’s healthy eye to repair the damaged cornea.
The study, involving 14 patients followed for 18 months, demonstrated the effectiveness and safety of CALEC. Lead investigator Dr. Ula Jurkunas, associate director of the Cornea Service at Mass Eye and Ear in Boston, highlighted the treatment’s high effectiveness, with over 90% success in restoring the cornea’s surface. This is especially important for people with serious corneal damage, like those with corneal ulcers. In these cases, regular corneal transplants may not be a good treatment option.
You May Also Like
The limbus, the outer layer of the cornea, is rich in limbal epithelial cells, a type of stem cell that constantly refreshes the cornea. When these cells are lost because of injury or disease, it causes limbal stem cell deficiency. This can lead to lasting damage to the cornea and may cause blurred vision.
How Does CALEC Work?
CALEC involves a meticulous process. Healthy stem cells are harvested from the patient’s healthy eye and expanded into a tissue graft over two to three weeks. This graft is then surgically transplanted into the damaged eye through eye surgery, restoring the cornea’s healing capacity. The study showed that CALEC fully restored the cornea in half of the participants in three months. The success rate rose to about 80% after 18 months. Including those with partial recovery, the overall success rate reached around 90%.
The safety of the procedure is also important. No serious problems were reported in the donor or the damaged eye.
You May Also Like
How Can CALEC Help Black Patients?
CALEC offers a treatment that uses the patient’s own cells or cells from deceased donors. This could lessen the need for living donors. This is especially helpful for Black patients who often struggle to find good matches. Researchers are looking into using it to treat other eye problems. One of these is Fuchs Dystrophy, which affects the cornea’s inner layer. This is essential for patients with pre-existing medical conditions.
While CALEC represents a significant advancement, it is still experimental and requires further clinical trials before FDA approval. Currently, the procedure requires a healthy eye to serve as a stem cell donor. However, researchers are exploring the possibility of using stem cells from deceased donors, which would expand who can access the treatment, especially for patients with damage to both eyes. This advancement could particularly benefit Black patients who may face disparities in access to living donors for allogenic transplant.
Addressing Inconsistencies in Eye Health for Black Patients
It is crucial to acknowledge that Black individuals may experience inconsistencies in eye health, including higher rates of certain eye conditions like glaucoma and diabetic retinopathy. These issues can be attributed to various factors, including limited access to eye exams and preventive care, as well as socioeconomic factors. The development of CALEC offers a potential solution to address some of these disparities.
Furthermore, the high success rate and safety profile of CALEC could lead to improved visual outcomes and quality of life for Black patients with corneal damage. This could have a significant impact on their overall well-being and ability to participate in daily activities.
In addition to CALEC, other areas of research, such as bone marrow transplant and novel eye drops that promote corneal healing, hold promise for addressing corneal damage. These advancements could further expand the treatment options available to Black patients and help reduce disparities in eye care.
By continuing to research and develop new treatments like CALEC, we can work towards better eye health for everyone. We must also address the factors that cause differences in eye care. Our goal is a future where all people, no matter their race, can access the best eye care.
